Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
February 14, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing...
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
January 23, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative...
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
January 08, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing...
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
December 28, 2023 09:15 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative...
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
December 18, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology
December 08, 2023 08:05 ET
|
Sight Sciences, Inc.
Prospective, long-term trial results are consistent with the significant body of published clinical evidence demonstrating the durable safety and effectiveness of procedures enabled with the OMNI...
Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023
November 07, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing...
Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023
October 24, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023
October 19, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...
Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting
October 12, 2023 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...